Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells
22Citations
1Influential
Ovarian cancer (OC) poses a significant challenge for conventional chimeric antigen receptor-engineered T (CAR-T) cell therapy, due to frequent recurrence linked to tumor heterogeneity, platinum resistance, immune evasion, and an immunosuppressive tumor microenvironment (TME). Here, we analyze primary OC patient samples and identify a unique opportunity for allogeneic CAR-NKT ( Compared to conventional CAR-T cells, These findings underscore the unique efficacy and safety advantages, as well as the off-the-shelf potential of Major funding was provided by the California Institute for Regenerative Medicine (CIRM).